ResMed's 12-14% EPS Growth Target Reframes GLP-1 as Demand Driver, Bolsters Bull Case

What happened

During a Morgan Stanley discussion, ResMed management outlined a target of 12%-14% EPS growth, explicitly attributing part of that outlook to GLP-1 patients lifting demand for sleep therapy. This directly challenges the prevailing bearish narrative that GLP-1 drugs would reduce PAP initiation and resupply, instead positioning the drugs as a potential demand catalyst. The master report's base case anticipated 8%-10% core sleep revenue growth and stable masks outpacing devices, so this higher EPS target suggests management sees stronger operating momentum than the market's current discount implies. However, the target likely includes a meaningful contribution from share repurchases funded by the MatrixCare sale, so underlying organic growth still needs to be confirmed in upcoming filings. The news is positive but should be treated as forward guidance until audited results verify that higher GLP-1 user adherence translates into durable device and consumable growth.

Implication

The new growth target aligns with and slightly exceeds the master report's base case, boosting confidence in the potential buy. GLP-1 data appears to be turning from a perceived threat into a demand catalyst, as management cites higher PAP initiation and resupply among GLP-1 users. However, investors should treat this as management guidance until audited results confirm that masks continue to outgrow devices and gross margins hold above 62%. The looming risk remains Philips' eventual U.S. re-entry, which could pressure pricing and share. Repurchases will support EPS, but core operating growth must remain unit-led rather than discount-led for the thesis to hold.

Thesis delta

The original thesis assigned only a 25% probability to the bull case where GLP-1 fears fade; management's explicit claim that GLP-1 patients are lifting demand shifts the balance toward that scenario. If corroborated by independent data, the bear case that GLP-1 adoption reduces OSA treatment volumes becomes less likely, increasing conviction in the potential buy. However, the shift relies on management's own analysis and forward guidance, so it requires verification through sustained mask and device growth before fully discounting the GLP-1 risk.